MCE products for research use only. We do not sell to patients.

Ibutamoren Mesylate

MCE China：Ibutamoren Mesylate

Brand：MedChemExpress (MCE)

Cat. No.HY-50844

CAS：159752-10-0

Synonyms：MK-677; MK-0677

Purity：99.86%

Storage：4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.

In Vivo：Ibutamoren mesylate (5 mg/kg/day) results in a statistically significant increases body weight gain and increases serum IGF-1 and GH levels in dogs. Ibutamoren mesylate results in no significant increase in CSF IGF-1 or GH levels on days 7 or 15 of the study[1]. Pretreating mice with GH blocks activation of these neurons by Ibutamoren mesylate (50 μg, i.p.). In the knockout mice, both GH and octreotide fail to inhibit Ibutamoren mesylate activation of arcuate neurons[2]. Chronic oral administration of Ibutamoren mesylate is associated with significant increases in GH and IGF-I levels that are maintained for the duration of the treatment. The GH profile following Ibutamoren mesylate administration consists of episodic increases above control[3]. Ibutamoren mesylate significantly increases peak GH concentrations after oral administration. Ibutamoren mesylate is a potent GH secretagogue that induces an immediate, large, long lasting increase in GH levels when administered orally or i.v[4].

Animal Administration：Compounds used are: Ibutamoren mesylate (50 μg), octreotide (100 μg), and mGH (30 μg). Mice are give an initial ip injection (0.1 mL) of either saline, octreotide or mGH, followed 10 min later by an ip injection (0.1 mL) of either saline or Ibutamoren mesylate. Thus, the first study comprised of the following groups: saline/saline, saline/Ibutamoren mesylate, mGH/saline, mGH/Ibutamoren mesylate saline/saline, saline/Ibutamoren mesylate, mGH/saline, mGH/Ibutamoren mesylate, and the second study of: saline/saline, saline/Ibutamoren mesylate, octreotide/saline, octreotide/Ibutamoren mesylate. Additionally, a number of mice are injected ip with hypertonic saline (0.2 mL, 1.5 M) to serve as positive controls for the immunocytochemistry. Ninety minutes after injection animals are terminally anesthetized with sodium pentobarbitone (60 mg/kg, ip) and perfused transcardially with heparinized saline followed by 4% paraformaldehyde in 0.1mol/Lphosphate buffer (PB, pH 7.4). Brains are then removed and placed in the same solution for 24 h before being stored at− 80°C until processing. Coronal sections of forebrain (40 μM) are cut on a freezing microtome and placed in 0.1mol/LPB containing Triton X-100 (PB-T, pH 7.4). Sections are incubated for 24 h at 4°C in Ab-2 Fos antibody (rabbit polyclonal; 1:1000 in 1% normal sheep serum). The antibody-antigen complex is localized with a 1-h incubation in biotinylated anti-rabbit Ig, followed by a 1-h incubation in avidin, biotinylated horseradish peroxidase. The reaction product is visualized using a glucose oxidase-diaminobenzidine-nickel method, and Fos-like immunoreactivity is visualized as a dense purple-black precipitate restricted to the nucleus. The number of c-fos positive nuclei in the arcuate and periventricular nuclei (six to eight sections per mouse) are counted double-blind and a group mean calculated (mean±sem). Statistical analysis is performed by a two-way ANOVA followed by an all pairwise multiple comparison of data with significance taken as P

Hot selling product：CD1530  | GW 441756  | Nelarabine  | Nitro blue tetrazolium chloride  | Oseltamivir  | Dracorhodin perchlorate  | Fluvastatin (sodium)  | Istaroxime (hydrochloride)  | Methylprednisolone succinate  | Canagliflozin (hemihydrate)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Prahalada S, et al. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7.  [Content Brief]

[2]. Zheng H, et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrinol. 1997 Oct;11(11):1709-17.  [Content Brief]

[3]. Hickey GJ, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997 Feb;152(2):183-92.  [Content Brief]

[4]. Jacks T, et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology. 1996 Dec;137(12):5284-9.  [Content Brief]